BlossomHill Therapeutics, Inc. (BLSM): Insider Trading, Congress Trades & Research | Tormere

BLSM

$15.76-3.87%download financials (.py)

BlossomHill Therapeutics, Inc.

Market Cap

$427M

As of 2026-10-16

Sector

Health Care

Industry

Pharmaceutical Preparations

Beta (raw)

—

Insufficient price history

P/E (TTM)

—

Price / TTM diluted EPS

P/S (TTM)

—

Price / TTM revenue

P/B

N/M

Price / stockholders equity

EV/EBITDA

—

TTM

Price Chart

Loading…

Signals

Insider Velocity

purchases / sales, 90d

Market & Alt Data

News

15

recent articles

Analyst Consensus

Strong Buy

11 analysts

Velocity Score

27.73x

Avg Daily Buying (90d)

17,488 sh/day

Baseline Daily Buying

0.0 sh/day

Unique Buyers (90d)

6

Sort by

Type

Trade Date	Filed	Owner	Role	Type	Shares	Price	Value	Owned After
2026-08-10	2026-08-12	GORDON CARL L	Director	Purchase	625.0K	$16.00	$10.00M	2.71M	View
2026-08-10	2026-08-12	ORBIMED ADVISORS LLC	Director	Purchase	625.0K	$16.00	$10.00M	2.71M	View
2026-08-10	2026-08-10	Keyes Jason A	Chief Financial Officer	Purchase	700	$16.00	$11K	700	View
2026-08-10	2026-08-10	Schmid John P.	Director	Purchase	6,000	$16.00	$96K	6,000	View
2026-08-10	2026-08-10	Chen Bihua	Director	Purchase	312.5K	$16.00	$5.00M	3.61M	View

1–5 of 7

1 / 2

Reporting Insiders

Recent News

BlossomHill Therapeutics (NASDAQ:BLSM) Shares Up 8.1% - Should You Buy?

MarketBeat · 2026-10-26

BlossomHill Therapeutics, Inc. Estimates – NASDAQ:BLSM

TradingView · 2026-10-25

BlossomHill Therapeutics Announces Collaboration with Foundation Medicine to Develop First Companion Diagnostic for BH-30643 in EGFR C797S Mutated Non-Small Cell Lung Cancer

Yahoo · 2026-10-22

BlossomHill Therapeutics Collaborates With Foundation Medicine To Develop Companion Diagnostic Assay For EGFR C797S Resistance Mutation

Benzinga · 2026-10-22

BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer

Yahoo · 2026-09-28

BlossomHill Therapeutics Presents Preclinical Data On BH-501284 At AACR Conference On Pancreatic Cancer; Targets IND Filing In Q1 2027

Benzinga · 2026-09-28

BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results

Yahoo Finance · 2026-09-18

BlossomHill Therapeutics Shares Rise 4.4% After BH-30643 Trial Update

Yahoo Finance · 2026-09-15

BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at IASLC 2026 World Conference on Lung Cancer

Yahoo Finance · 2026-09-15

BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit & H.C. Wainwright 28th Annual Global Investment Conference

Yahoo Finance · 2026-09-03

BlossomHill Therapeutics, Inc. Rings the Nasdaq Stock Market Opening Bell

Nasdaq · 2026-09-03

BlossomHill Therapeutics to Present Updated Data from Ongoing Phase 1/2 SOLARA Trial of its Macrocyclic OMNI-EGFR™ Inhibitor, BH-30643, in EGFR-mutant NSCLC at the 2026 World Conference on Lung Cancer

Yahoo Finance · 2026-09-01

Insiders Are Betting Big on These 3 Healthcare Stocks

Yahoo Finance · 2026-08-31

symbol__ Stock Quote Price and Forecast

CNN · 2026-08-09

Cancer drug developer BlossomHill slips post IPO (BLSM:NASDAQ)

Seeking Alpha · 2026-08-07

Informational purposes only, not investment advice.

Recent Insider Activity (Form 4) — Last 5

Date	Insider	Type	Shares	Value
2026-08-10	GORDON CARL L	P	625,000	$10M
2026-08-10	ORBIMED ADVISORS LLC	P	625,000	$10M
2026-08-10	Keyes Jason A	P	700	$11,200
2026-08-10	Schmid John P.	P	6,000	$96,000
2026-08-10	Chen Bihua	P	312,500	$5M